SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Novo Nordisk A/S Securities and Sets a Lead Plaintiff Deadline of March 25, 2025

Core Viewpoint - A class action lawsuit has been initiated against Novo Nordisk A/S due to disappointing results from their "REDEFINE 1" trial, which led to a significant drop in the company's stock price [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit, titled Changyeon Moon v. Novo Nordisk A/S, was filed in the United States District Court for the District of New Jersey [1]. - The lawsuit affects all individuals or entities that purchased Novo Nordisk securities between November 2, 2022, and December 19, 2024 [1]. Group 2: Trial Results - The "REDEFINE 1" trial, which investigated the efficacy and safety of subcutaneous CagriSema, reported a weight loss of 22.7% after 68 weeks, falling short of the company's target of at least 25% [3]. - Only 57.3% of patients in the trial were on the highest dosage, as participants were allowed to modify their own dosages during the study [3]. Group 3: Stock Market Impact - Following the announcement of the trial results, Novo's stock price decreased by $18.44, closing at $85.00 per share [4].